Common liver diseases and World Hepatitis Day 2018

World Hepatitis Day is observed on 28 July each year. It aims to raise global awareness of hepatitis and encourage prevention, diagnosis and treatment. World Hepatitis Day is one of eight official global public health campaigns marked by the World Health Organization (WHO).

For people living with Hepatitis C (HCV), it is an exciting time. The introduction of direct-acting antiviral (DAA) therapies for HCV that are highly effective and well tolerated is a major medical advance. All Australians living with HCV should now be considered for antiviral therapy.

Receiving treatment in familiar environments with their trusted, accessible, long-term doctors removes an important barrier to treatment and will improve the cascade of care. Evidence from the interferon era supports the efficacy of GP-led treatment with remote specialist supervision. Primary care based treatment is suitable for most people living with HCV, in particular those with mild–moderate liver fibrosis. To support this, the availability and interpretation of simple tools for liver fibrosis assessment in the community is very important. People with cirrhosis, complex comorbidities or other types of liver disease, or in whom first-line DAA therapy has failed, should still be referred for specialist care.

To learn about local options for Hepatitis C prescribing support in the GP setting, including access to fibroscan, come along to the CPD event "Common Liver Diseases in Australia: Diagnosis, Assessment and Management" at 6.30 pm 26 July, Ashfield.

Click here to register.